)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Drägerwerk
Drägerwerk (DRW3) investor relations material
Drägerwerk Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary30 Jul, 2026
Executive summary
Net sales rose sharply by 7.7% to €1,603 million in H1 2026, with strong growth in both medical and safety divisions and particularly robust performance in the Americas, EMEA, and Germany.
EBIT more than tripled to €63.8 million, with margin up to 4.0%, driven by higher sales, improved gross margin, and a one-off customs refund.
Free cash flow turned positive at €15.5 million, reflecting operational strength and improved profitability.
Order intake increased slightly to €1,747 million, with medical segment impacted by a prior-year major order and safety segment showing strong demand.
Earnings benefited from strong operating momentum and a one-off U.S. customs refund.
Financial highlights
Net sales increased by 7.7% in H1 2026 to €1,603 million; gross margin improved by 1.7 percentage points to 46.5%.
EBIT rose from €20 million to €63.8 million in H1, with margin up from 1.3% to 4.0%.
Free cash flow improved to €15.5 million from -€42 million year-over-year.
ROCE increased to 15.7% (from 9.9% in H1 2025).
Earnings after income taxes reached €40.2 million, up from €9.5 million year-over-year.
Outlook and guidance
Net sales growth for 2026 expected at 2.0–6.0% (currency-adjusted); EBIT margin guidance raised to 6.0–8.0% due to strong operations and customs refunds.
DVA guidance increased to €60–140 million; days working capital target lowered to 100–105 days.
Targeting EBIT margin improvement of one percentage point per year to reach 10% by 2030.
Guidance raised due to strong operating business and customs refunds.
Further customs refunds of €7–9 million are possible but not guaranteed.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Drägerwerk
- 2025 saw higher sales, margin gains, and top sustainability ratings, with profitability prioritized.DRW3
Investor presentation - Strong Q1 with higher sales, improved margins, and robust outlook for 2026.DRW3Q1 2026
- Record 2025 sales, margin growth, and innovation drive a strong outlook and defense expansion.DRW3German Select VII Conference
- 2025 sales reached €3.5bn with rising profitability and a focus on innovation and sustainability.DRW3Investor presentation
- Record sales, higher EBIT, and increased dividends marked robust growth in 2025.DRW3Q4 2025
- Safety division growth and one-off gains drive higher earnings despite medical segment decline.DRW3Q3 2024
- EBIT and net profit rose despite lower sales, led by safety division growth and one-off gains.DRW3Q2 2024
- Order intake hit a five-year Q1 high, but earnings fell as medical margins declined.DRW3Q1 2025
- EBIT up 17% to EUR 194M, stable sales, 2025 outlook: 1%-5% growth, higher dividend.DRW3Q4 2024
Next Drägerwerk earnings date
Q3 202629 Oct, 2026
Drägerwerk
Next Drägerwerk earnings date
Q3 202629 Oct, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Drägerwerk AG & Co. KGaA, commonly referred to as Dräger, is a company active in the fields of medical devices and safety technology. It specializes in developing, producing, and marketing system solutions, equipment, and services across the acute point of care (APOC) process chain. This includes areas such as emergency care, perioperative care, critical care, perinatal care, and home care. Beyond its medical technology portfolio, Dräger also provides professional diving equipment, alcohol and drug detection devices, and a range of safety equipment and system solutions for personal protection, stationary and mobile gas detection, as well as integrated hazard management. Drägerwerk is headquartered in Lübeck, Germany, and its shares are listed on the Frankfurt Stock Exchange.